PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.

Abstract

BACKGROUND:

PREPARED was a randomized, parallel-group, double-blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD).

METHODS:

Patients received once-daily PR (2-24 mg/d; n = 177) or three-times-daily IR (0.75-24 mg/d; n = 173) for 24 weeks. The primary endpoint was the proportion of patients maintaining ≥ 20% reduction from baseline in "off" time over two consecutive visits at Week 24 last observation carried forward (LOCF).

RESULTS:

At Week 24 LOCF, PR significantly increased the proportion of patients maintaining ≥ 20% reduction in "off" time versus IR (adjusted odds ratio: 1.82; 95% CI: 1.16, 2.86; P = 0.009). Mean (SD) doses at Week 24 LOCF were: PR, 18.6 (6.5) mg/d; IR, 10.4 (6.4) mg/d; mean (SD) reductions from baseline in levodopa (L-dopa) dose were -162 (226) mg and -113 (138) mg, respectively. Adverse events (AEs) were reported by 72% of patients in the PR group and 61% in the IR group; 12% and 9% of patients, respectively, withdrew from the study due to an AE, and 6% and 5%, respectively, reported serious AEs.

CONCLUSIONS:

Adjunctive PR provided a significantly greater improvement in symptom control in terms of the odds of achieving ≥ 20% maintained reduction in time spent "off" compared with IR. Interpretation may be confounded by the higher doses of PR versus IR that were achieved, in combination with lower doses of L-dopa by the study end. Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR.

• Authors: Fabrizio Stocchi, Luigi Giorgi, Brian Hunter, Anthony H V Schapira
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 26 Issue 7 Pg. 1259-65 (Jun 2011) ISSN: 1531-8257 [Electronic] United States
• PMID: 21469195 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Movement Disorder Society.

Chemical References

• Antiparkinson Agents
• Delayed-Action Preparations
• Indoles
• ropinirole
• Levodopa

Topics

• Aged
• Antiparkinson Agents (administration & dosage, adverse effects)
• Delayed-Action Preparations (administration & dosage, adverse effects)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Humans
• Indoles (administration & dosage, adverse effects)
• Levodopa (administration & dosage)
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Severity of Illness Index
• Treatment Outcome